Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK5926371
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GSK5926371 is an investigational B-cell depleting T-cell engager (TCE) developed by GSK for the treatment of autoimmune rheumatic diseases (ARD). The molecule is designed to simultaneously bind to CD19 and CD20 on B-lymphocytes and CD3 on T-lymphocytes. This dual-targeting approach aims to achieve more comprehensive B-cell depletion than therapies targeting only one marker (like rituximab), potentially eliminating pathogenic B-cell populations that contribute to chronic inflammation. It is currently being evaluated in the Phase 1 ELEVATE-1 clinical trial for several B-cell driven conditions, including systemic lupus erythematosus, rheumatoid arthritis, idiopathic inflammatory myopathies, and Sjogren's disease.
- Other names
- CD19/CD20 T-cell engager
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on GSK5926371.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK5926371.